Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 6021

Next Previous
X
Search
Drug Profile

BAT 6021

Alternative Names: BAT-6021

Latest Information Update: 17 Oct 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Oct 2023 Bio-Thera Solutions terminates a phase I trial for Solid Tumor (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in Australia (IV) due to strategic reasons (NCT05073484)
  • 08 Oct 2023 Bio-Thera Solutions terminates a phase-I clinical trial in Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease) in China (IV), based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline (NCT05120375)
  • 17 Feb 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in China (IV) (NCT05120375)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top